Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine

Francesco Napolitano, Alessandra Bonito-Oliva, Mauro Federici, Manolo Carta, Francesco Errico, Salvatore Magara, Giuseppina Martella, Robert Nisticò, Diego Centonze, Antonio Pisani, Howard H. Gu, Nicola B. Mercuri, Alessandro Usiello

Research output: Contribution to journalArticlepeer-review

Abstract

Attention deficit/hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and motor hyperactivity. Several lines of research support a crucial role for the dopamine transporter (DAT) gene in this psychiatric disease. Consistently, the most commonly prescribed medications in ADHD treatment are stimulant drugs, known to preferentially act on DAT. Recently, a knock-in mouse [DAT-cocaine insensitive (DAT-CI)] has been generated carrying a cocaine-insensitive DAT that is functional but with reduced dopamine uptake function. DAT-CI mutants display enhanced striatal extracellular dopamine levels and basal motor hyperactivity. Herein, we showed that DAT-CI animals present higher striatal dopamine turnover, altered basal phosphorylation state of dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP32) at Thr75 residue, but preserved D2 receptor (D2R) function. However, although we demonstrated that striatal D1 receptor (D 1R) is physiologically responsive under basal conditions, its stimulus-induced activation strikingly resulted in paradoxical electrophysiological, behavioral, and biochemical responses. Indeed, in DAT-CI animals, (1) striatal LTP was completely disrupted, (2) R-(+)-6-chloro-7,8- dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) treatment induced paradoxical motor calming effects, and (3) SKF 81297 administration failed to increase cAMP/protein kinase A (PKA)/DARPP32 signaling. Such biochemical alteration selectively affected dopamine D1Rs since haloperidol, by blocking the tonic inhibition of D2R, unmasked a normal activation of striatal adenosine A2A receptor-mediated cAMP/PKA/DARPP32cascade in mutants. Most importantly, our studies highlighted that amphetamine, nomifensine, and bupropion, through increased striatal dopaminergic transmission, are able to revert motor hyperactivity of DAT-CI animals. Overall, our results suggest that the paradoxical motor calming effect induced by these drugs in DAT-CI mutants depends on selective aberrant phasic activation of D1R/cAMP/PKA/ DARPP32 signaling in response to increased striatal extracellular dopamine levels.

Original languageEnglish
Pages (from-to)11043-11056
Number of pages14
JournalJournal of Neuroscience
Volume30
Issue number33
DOIs
Publication statusPublished - Aug 18 2010

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Role of aberrant striatal dopamine D<sub>1</sub> receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine'. Together they form a unique fingerprint.

Cite this